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Dterminated follow-up at 30 days after surgery, but longer-
term follow-up is more relevant, particularly because a
significant proportion of thrombosis-related complications
occur beyond the 30-day time frame. Third, the incidence
of thrombosis may be underestimated by this study because
echocardiography does not detect peripheral vessel
thrombosis.
In conclusion, this study demonstrates that aspirin
unresponsiveness occurs in approximately 10.4% of
patients undergoing specific high-risk congenital cardiac
procedures using the dosing practice of a single institution.
Aspirin unresponsiveness as measured by the VerifyNow
system predicts the 30-day risk of thrombosis in patients
after specific complex cardiac surgical procedures. Future
studies are necessary to demonstrate if monitoring of
aspirin therapy with consequent dose adjustment or addition
of alternative agents for unresponsive patients minimizes
the risk of thrombosis in this cohort.References
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Dr Jennifer Hirsch-Romano (Ann Arbor, Mich). Thank you,
Ram, for an excellent presentation. You really highlight a
significant problem in the congenital heart disease population.
Thromboses in these patients can span from being just challenging
peripheral venous thromboses that make central access incredibly
difficult as these patients age to fatal shunt thrombosis. I think the
understanding of aspirin resistance is really new to our field and we
are just getting new information with studies such as yours. I am
hoping that with a better understanding of aspirin resistance as
well as various antithrombotic agents, we will get a better
understanding of how to manage our patients.
My first question to you is: in all of our neonates, we routinely
use a 40.5-mg dose. I am interested to know whether the high rate
of aspirin unresponsiveness as well as the high thrombosis rate in
your neonates have led to changes in any of the practice
management in your own institution in terms of that dosing.
Dr Emani. A proposed algorithm reflecting the findings of our
study includes the use of a higher dose of 40.5 mg aspirin in
neonates greater than 3 kg. We are hesitant to use 40.5 mg in
patients less than 2.5 kg. But we have started using 40 mg more
commonly in the neonates. The data would support being
more aggressive about testing neonates and then considering a
dose adjustment if unresponsive.
Dr Hirsch-Romano. My next question has to do with the
screening you did within your study. I know you specifically did
echo monitoring for intracardiac thromboses and otherwise fol-
lowed for clinical events. Have you considered doing any routine
screening for peripheral thromboses? Quite often the loss of
venous access in these children is silent without obvious signs of
limb ischemia.
Dr Emani. I think we need to be more thorough in our assess-
ment of peripheral vascular thrombosis, which is under-reported.
In this study, only clinically significant events such as limb
ischemia were used to define peripheral thrombosis. Imaging
studies are suboptimal at detecting asymptomatic events. I thinkery c September 2014
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Dmoving forward, we are going to have to be much more systematic
about imaging and detecting these types of events. Fortunately, the
methodology was consistent among all patients, so although we
may be underestimating the incidence of thrombosis, the relation-
ship of thrombosis to aspirin unresponsiveness still holds true.
Dr Hirsch-Romano. Then my final question has to do with the
use of Plavix. I think the use of Plavix in the pediatric population is
still a bit controversial, but it is certainly increasing at many
congenital heart centers. Are you using Plavix in your pediatric
population; and if so, for what indications?
Dr Emani. Plavix, as you know, also has its downsides. About
20% to 25% of patients are Plavix unresponsive, and the bleeding
risk is higher. But I would certainly use Plavix for a patient who is
at high risk for thrombosis and is resistant to aspirin.
According to our proposed algorithm, in a patient who is unre-
sponsive, if you really want to understand if is this an absorption
issue versus inadequate dosing, you can actually spike the blood
with a maximum dose of aspirin to determine true resistance. I
think in a truly resistant patient I would use Plavix, but would
test for the effect of Plavix as well.
Dr Hirsch-Romano. Can you tell me about your VerifyNow
testing? I know historically when we had a look at various testing
options, quite often they require a fair blood volume, which is chal-
lenging in a neonatal population, or they require a nontourniquet
blood draw, which also can be challenging.
Dr Emani. It requires 2 mL of blood and that is a major issue.
We are working with a couple of different systems, microfluidic
systems, to try to reduce that volume.
A major problem with platelet testing, particularly if you use
small-volume draws, is the hypersensitive nature of the clotting
system after introducing any foreign object into the blood stream.
So a finger stick or a small-volume blood draw is likely to be
contaminated by the contact activation. So novel methods of in
vivo platelet reactivity testing need to be developed to overcome
this limitation.
Dr Henry Walters (Detroit, Mich). This was an excellent pre-
sentation. Jenna, you had mentioned the catastrophic situation in
which there is thrombosis of a systemic-to-pulmonary artery
shunt. If we are still in the mood for surveys, I was wondering if
we could conduct another one.
Dr Carl L. Backer (Chicago, Ill). We are in the mood. Go
ahead.
Dr Walters. Great. Well, I am going to leave the survey
questions up to you, but, for example, after constructing a
systemic-to-pulmonary artery shunt, 1 program might start with
an intravenous heparin infusion and transition to some kind of
antiplatelet agent. Others might use aspirin only, Plavix only, or
a combination. I would be interested in how the members of this
audience approach this situation.
Dr Backer. Dr Hirsch-Romano has already read your mind and
I have got a list here.
For a neonate having a modified Blalock-Taussig shunt (our
biggest fear I think for thrombosis), how many surgeons would
use aspirin only?
(Show of hands.)
It looks like about a third of the hands.
And how many would use Plavix only? Nobody is using
Plavix only.The Journal of Thoracic and CaHow about aspirin plus Plavix?
Nobody. There is no Plavix.
What about heparin, intravenous heparin therapy?
Dr Hirsch-Romano. Heparin bridge to aspirin.
Dr Backer. Heparin bridge to aspirin.
(Show of hands.)
Oh, boy, now everybody’s hands are going up. We have got
about 80% of the audience.
How about Lovenox, injections of Lovenox; who uses
Lovenox?
(Show of hands.)
Only 3 hands for Lovenox.
It seems that most surgeons when they are really concerned
about thrombosis are using heparin followed by aspirin. What
are your thoughts about that Ram?
Dr Emani. I use heparin followed by aspirin, partly because I
do not think there is a great antiplatelet agent for the immediate
postoperative period. When we looked at shunt thrombosis in
particular, it is actually white thrombus suggesting platelet
aggregation rather than thrombosis mediated by the coagulation
system, so an antiplatelet agent is actually what you need.
The question is whether you can do that safely and effectively
with current therapeutic options. But I still use heparin and try
to get it therapeutic before initiation of aspirin.
Dr Sabine Daebritz (Duisburg, Germany). It was an interesting
talk. Did you screen your patients for any other reasons for throm-
bosis like factor V Leiden or heparin-induced thrombocytopenia?
This is important because some of those thromboses, like sagittal
sinus thrombosis, are not considered to be influenced much by
aspirin so they might be caused by something else.
Dr Emani. Yes, many of the patients with thrombosis are
screened for hypercoagulability disorders as well. Some of the
neonates and single-ventricle patients who do not have
thrombosis were screened with a thrombophilia panel as a part
of a separate study. We have found that the presence of a hyperco-
agulability disorder increases the risk of a thrombosis event. The
patient who had sagittal sinus thrombosis particularly did not
have a coagulation abnormality, nor did any of the other patients
who had thrombosis. We did not systematically screen all patients
without thrombosis.
But I would add that even if thrombophilia panels come back
negative, it does not mean that a child does not have some form
of hypercoagulability disorder or platelet hyperreactivity. I would
argue that all high-risk patients should therefore be aggressively
managed with anticoagulation or antiplatelet therapy?
Dr Joseph J. Amato (Chicago, Ill). I was just curious, when
you were doing the diagnosis of atrial septal defect, youmentioned
that a certain percentage, a small percentage, were looked at with
catheterization. Is that a necessity or it just so happened?
Dr Emani. The patients who underwent catheterization for
hemodynamic reasons would have been followed for a thrombosis
event. So we have looked at those images to see if thrombosis
was present as an incidental finding. None of the patients had
thrombosis detected by catheterization alone.
Dr Amato. You could have defined them by just echo alone?
Dr Emani. Right. Most of the catheterizations that occurred
were performed for hemodynamic reasons rather than confirma-
tion of echo.rdiovascular Surgery c Volume 148, Number 3 815
Congenital Heart Disease Emani et al
C
H
DDr J.WilliamGaynor (Philadelphia, Pa). Ram, I enjoyed that.
One quick question. There are obviously multiple factors that can
play into the risk of thrombosis, and 1 of those is the shunt itself.
This is completely anecdotally, but a few years ago we switched to
the heparin-bonded shunts and it seems like our rate of thrombosis
(we still use heparin as a bridge to aspirin), but it seems like our
rate of early shunt thrombosis has decreased with that. We have
not looked at it systemically. It is anecdotal. I was wondering
what shunt material you used?
Dr Emani.Well, I was excited when the heparin-bonded shunt
came out and I use that on all of my patients and I have not found a
difference.
The patients who develop thrombosis of polytetrafluoroethy-
lene material demonstrate platelet-mediated occlusion rather
than coagulation-mediated. So I am not sure if the heparin helps816 The Journal of Thoracic and Cardiovascular Surgmuch. As we start to understand the clotting system in general, I
think we can start to understand that there are actually therapies
in each of the systems; the coagulation platelet and fibrinolytic
systems. Hopefully as we collect more data, we can tailor our
approach based on what we think the predominant deficits are.
We need better monitoring systems and better therapeutic options.
Dr Backer. Bill, you bring up a good point. Let me survey the
audience. How many surgeons have switched to using the heparin-
bonded shunts?
(Show of hands.)
And how many are still using the non–heparin-bonded shunts?
(Show of hands.)
Looks like about 50/50 or maybe 60/40 for the heparin-bonded
shunts. Our group has certainly switched to them, and at least
anecdotally I have found that we have had less shunt thrombosis.ery c September 2014
